CDMO, CMO, Supplier Roundup in Supporting COVID-19 Projects

By Miranda Greenberg -

August 27, 2020

The latest from CDMOs/CMOs, suppliers, and other service providers in COVID-19 projects featuring Catalent, Ology Bioservices, and Clarivate.

Biologics Manufacturing

Catalent To Manufacture AstraZeneca’s COVID-19 Vaccine
Catalent reports that it will provide drug-substance manufacturing to AstraZeneca for AstraZeneca’s/University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene-therapy manufacturing facility in Harmans, Maryland.

Catalent will prepare the Harmans facility to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance beginning late in the third quarter of 2020. This agreement expands Catalent’s support of the AZD1222 program following the announcement in June (June 2020) that Catalent’s facility in Anagni, Italy, will provide large-scale vial filling and packaging of AZD1222.

The adenovirus vector-based vaccine candidate, AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca. The vaccine candidate is currently in clinical trials.

The Harmans facility is one of Catalent’s five gene-therapy facilities in Maryland providing clinical- through commercial-scale services, and houses multiple CGMP manufacturing suites, including fill–finish, central services and testing laboratories, warehousing, and supply-chain capabilities.

Source: Catalent


Ology in US Gov’t Contract for Mfg Capacity for COVID Vaccines, Drugs
Ology Bioservices, a biologics CDMO, has been awarded a contract, valued at $106.3 million, by the US Army Contracting Command to reserve production capacity in support of Operation Warp Speed, a US government initiative to accelerate the development of vaccines and treatments against COVID-19.

The contract ceiling value is $106.3 million, of which $53.1 million was obligated at the time of the award. In this program, Ology Bioservices will manage the reservation of production capacity of approximately 186,840,000 doses of vaccines and therapeutics for COVID-19.

Source: Ology Bioservices


General

Clarivate Launches Data Lake for Research for COVID, Future Pandemics
Clarivate, a provider of scientific, patent, and pharmaceutical and biotechnology business intelligence, has launched its Coronavirus, Virology, and Infectious Disease (CVID) Data Lake to support researchers and policy makers in making data-driven decisions. The CVID Data Lake is the first of several therapeutically oriented data lakes from Clarivate. The CVID Data Lake is a unified dataset focused on coronaviruses, including COVID-19, as well as virology, super viruses, and infectious diseases.

Source: Clarivate